X4 Pharmaceuticals, Inc. Common Stock

Day range

$3.14 – $3.30

Open

$3.26

Prev close

$3.24

Volume

701.11K

Market cap

$321.24M

Shares out

99.15M

P/E

—

P/S

20.27

P/B

2.07

P/FCF

—

ROE

-58.0%

ROA

-35.6%

Debt/Equity

0.49

Div yield

0.00%

As of Oct 23, 2026

• Credit facility drawOct 8, 2026

  The First Tranche Term Loan ... in the aggregate principal amount of $80.0 million ... was funded on the Closing Date. The Borrowers used a portion of the proceeds ... to repay in full all outstanding obligations under the Hercules Loan Agreement and intend to use the remaining proceeds for working capital and general corporate purposes.

• Investor presentationSep 9, 2026

  On September 8, 2026, X4 Pharmaceuticals, Inc. (the "Company") posted an updated corporate presentation on the Company's website. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

• Business updateSep 8, 2026

  On September 8, 2026, X4 Pharmaceuticals, Inc. (the "Company") issued a press release announcing the positive outcome of the Company's Type C Meeting with the U.S. Food and Drug Administration related to the global 4WARD Phase 3 clinical trial.

• Director appointmentJul 1, 2026

  On June 30, 2026, of X4 Pharmaceuticals, Inc. (the "Company") appointed Kelly Gold as a Class II director of the Company, effective as of July 1, 2026. In connection with Ms. Gold's appointment, the size of the Company's board of directors (the "Board") was increased from five to six directors. Ms. Gold has also been appointed to serve on the Audit Committee of the Board.

• Annual meeting resultsMay 12, 2026

  The final results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting are set forth below. These proposals are described in detail in the Proxy Statement. Proposal 1. Election of the three Class III director nominees to serve until the 2029 Annual Meeting of Stockholders... The Company's stockholders elected the persons listed below as director, to serve until the Company's 2029 Annual Meeting of Stockholders.

Days to cover

6.0

Short interest

7.59M

Avg volume

1.26M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
  positiveGlobeNewswire Inc.· Feb 27, 2026
• X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
  neutralGlobeNewswire Inc.· Oct 24, 2025
• Sitryx appoints Adam Mostafa as Chief Financial Officer
  neutralGlobeNewswire Inc.· Sep 8, 2025
• X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
  neutralGlobeNewswire Inc.· Aug 12, 2025
• X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
  positiveGlobeNewswire Inc.· Nov 13, 2024